ClinVar Miner

Submissions for variant NM_031885.5(BBS2):c.311A>C (p.Asp104Ala)

gnomAD frequency: 0.00003  dbSNP: rs121908179
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000587645 SCV000699657 pathogenic Bardet-Biedl syndrome 2016-06-30 criteria provided, single submitter clinical testing Variant summary: The c.311A>C (p.D104A) in BBS2 gene is a missense change that alters a conserved nucleotide and 5/5 in silico tools predict deleterious outcome. The variant was observed in the large and broad cohorts of the ExAC project at an allele frequency of 0.00005 exclusively in individuals of European descent (0.000075). This frequency does not exceed the maximal expected allele frequency for a pathogenic variant in BBS2 gene (0.0008). Fedick (2014) reports the carrier frequency of 0.473% (0.0071%) for Jewish population. The variant of interest has been reported in multiple BBS pts in compound heterozygous state and in 2 homozygous individuals presented with nonsyndromic autosomal recessive RP (Shevach, 2014). Taking together, the variant was classified as Pathogenic.
Fulgent Genetics, Fulgent Genetics RCV000762969 SCV000893410 pathogenic Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 2022-01-12 criteria provided, single submitter clinical testing
Invitae RCV000587645 SCV001224789 pathogenic Bardet-Biedl syndrome 2024-01-25 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with alanine, which is neutral and non-polar, at codon 104 of the BBS2 protein (p.Asp104Ala). This variant is present in population databases (rs121908179, gnomAD 0.1%). This missense change has been observed in individuals with Bardet-Biedl syndrome (PMID: 11567139, 21344540, 21642631, 23829372). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 4577). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt BBS2 protein function with a positive predictive value of 80%. Experimental studies have shown that this missense change affects BBS2 function (PMID: 20498079). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV001582466 SCV001819406 pathogenic not provided 2019-10-15 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect suggestive of a dominant negative mode of action (Zaghloul et al., 2010); This variant is associated with the following publications: (PMID: 31456290, 20498079, 23829372, 11567139, 19402160, 25541840)
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV001002876 SCV001950217 pathogenic Retinitis pigmentosa 2021-04-01 criteria provided, single submitter curation The p.Asp104Ala variant in BBS2 was identified in an individual with Retinitis pigmentosa, via a collaborative study between the Broad Institute's Center for Mendelian Genomics and the Pierce lab (https://oculargenomics.meei.harvard.edu/labs/pierce-lab/lab-members/). Through a review of available evidence we were able to apply the following criteria: PS3, PM2, PM3, PP1, PP3. Based on this evidence we have classified this variant as Pathogenic. If you have any questions about the classification please reach out to the Pierce Lab.
Broad Center for Mendelian Genomics, Broad Institute of MIT and Harvard RCV000190985 SCV002507053 pathogenic Retinitis pigmentosa 74 2022-05-04 criteria provided, single submitter curation The heterozygous p.Asp104Ala variant in BBS2 was identified by our study, along with another pathogenic variant, in 1 individual with retinitis pigmentosa 74. The variant has been reported in at least 4 Ashkenazi Jewish individuals with retinitis pigmentosa 74 (PMID: 23829372), and has been identified in 0.1% (10/10080) of Ashkenazi Jewish and 0.0009% (1/113746) of European non-Finnish chromosomes by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP ID: rs121908179). Although this variant has been seen in the general population, its frequency is not high enough to rule out a pathogenic role. This variant has also been reported in ClinVar (Variation ID: 4577) as pathogenic by Integrated Genetics/Laboratory Corporation of America, Invitae, OMIM, and Sharon lab, Hadassah-Hebrew University Medical Center, and as likely pathogenic by Counsyl and Fulgent Genetics. Animal models in zebrafish have shown that this variant causes retinitis pigmentosa 74 (PMID: 20498079). Computational prediction tools and conservation analyses suggest that this variant may impact the protein, though this information is not predictive enough to determine pathogenicity. The presence of this variant in 2 affected homozygotes, in combination with a reported pathogenic variant, and in 4 individuals with retinitis pigmentosa 74 increases the likelihood that the p.Asp104Ala variant is pathogenic (VariationID: 4578; PMID: 23829372). In summary, this variant meets criteria to be classified as pathogenic for retinitis pigmentosa 74 in an autosomal recessive manner based on its disease-causing effect in an animal model, and its homozygous occurrence and occurrence with other pathogenic variants in trans in affected individuals. ACMG/AMP Criteria applied: PS3, PM3_strong, PP3 (Richards 2015).
New York Genome Center RCV000762969 SCV003925420 pathogenic Bardet-Biedl syndrome 2; Retinitis pigmentosa 74 2022-02-23 criteria provided, single submitter clinical testing
Baylor Genetics RCV000665304 SCV004214013 pathogenic Bardet-Biedl syndrome 2 2023-08-31 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV004532290 SCV004766229 pathogenic BBS2-related disorder 2023-10-26 criteria provided, single submitter clinical testing The BBS2 c.311A>C variant is predicted to result in the amino acid substitution p.Asp104Ala. This sequence variant has been reported in multiple individuals with Bardet-Biedl syndrome 2 (OMIM #615981), retinitis pigmentosa 74 (OMIM #616562), and cone-rod dystrophy (Katsanis et al. 2001. PubMed ID: 11567139; Consugar et al 2015. PubMed ID: 25412400; Shevach et al 2015. PubMed ID: 25541840). This variant is reported in 0.099% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-56548399-T-G). This variant is interpreted as pathogenic.
OMIM RCV000004839 SCV000025015 pathogenic Bardet-biedl syndrome 1/2, digenic 2015-03-01 no assertion criteria provided literature only
OMIM RCV000190985 SCV000245872 pathogenic Retinitis pigmentosa 74 2015-03-01 no assertion criteria provided literature only
Counsyl RCV000665304 SCV000789398 likely pathogenic Bardet-Biedl syndrome 2 2017-01-30 no assertion criteria provided clinical testing
Sharon lab, Hadassah-Hebrew University Medical Center RCV001002876 SCV001160909 pathogenic Retinitis pigmentosa 2019-06-23 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.